U.S. Markets open in 8 hrs 51 mins

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.05+0.02 (+0.18%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.03
Open11.00
Bid0.00 x 800
Ask0.00 x 900
Day's Range10.80 - 11.29
52 Week Range6.26 - 16.53
Volume96,997
Avg. Volume221,803
Market Cap413.613M
Beta (5Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

    NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ: VYGR).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Voyager and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On October 12, 2020, Voyager issued a press release disclosing that it “has received feedback from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington’s disease.”  Specifically, Voyager advised investors that it “has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.” On this news, Voyager’s stock price fell sharply during intraday trading on October 13, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 7980

  • Why Voyager Therapeutics Stock Is Sinking Today
    Motley Fool

    Why Voyager Therapeutics Stock Is Sinking Today

    Shares of the clinical-stage gene therapy company Voyager Therapeutics (NASDAQ: VYGR) dropped by as much as 11% in pre-market trading Tuesday morning. The biotech's shares are responding negatively to a regulatory delay for its Huntington's disease candidate, VY-HTT01. After market close yesterday, Voyager announced that the Food and Drug Administration placed a clinical hold on the experimental gene therapy pending the resolution of certain chemistry, manufacturing, and controls (CMC) matters.

  • Voyager Plunges 11% As Huntington’s Treatment Placed On Clinical Hold
    SmarterAnalyst

    Voyager Plunges 11% As Huntington’s Treatment Placed On Clinical Hold

    Shares in Voyager Therapeutics (VYGR), a clinical-stage gene therapy company, plunged 11% in Monday’s after-hours trading. The company revealed that the U.S. Food and Drug Administration (FDA) has placed its Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington’s disease on clinical hold.The IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters, says the company.Voyager now expects to receive specific feedback from the FDA on these matters within 30 days and plans to work closely with the agency to resolve them and promptly begin the clinical evaluation of VY-HTT01. It submitted the IND for VY-HTT01 in September 2020.Huntington’s disease is a fatal, inherited neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain. It is the most common monogenic neurological disorder in the developed world but there are no approved treatments targeting the underlying cause of the disease.Shares in Voyager Therapeutics are currently trading down 14% year-to-date, however the stock scores a bullish Strong Buy consensus from the Street. That’s with 6 recent buy ratings vs 2 hold ratings. Meanwhile the average analyst price target of $19 indicates 59% upside potential from current levels.Oppenheimer analyst Jay Olson has a buy rating on the stock and $26 price target based on his optimism over the company’s pipeline therapy for Parkinson’s Disease.“Our Outperform rating on VYGR is based on our belief that shares are undervalued according to our evaluation of the company’s main asset, VY-AADC, and its Ph2/3 registrational clinical trials for advanced Parkinson’s Disease patients” he explained.Currently, advanced Parkinson’s Disease patients may be candidates for Deep Brain Stimulation surgery and a relatively small number of patients typically pursue this procedure. “We believe that VY-AADC is well positioned to offer an additional option for advanced Parkinson’s Disease patients, given VYGR’s unique combination of AAV delivery and AADC-targeting gene therapy” the analyst concluded. (See VYGR stock analysis on TipRanks).Related News: J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine More recent articles from Smarter Analyst: * Nestlé Completes Tender Offer For 84% Stake In Aimmune Therapeutics * New Oriental Rises On Solid Earnings Beat Despite Covid-Headwinds * Altimmune's COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside * Sanofi, Regeneron’s Dupixent Significantly Reduces Children’s Asthma Attacks